OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Oxford, UK – 20 February 2025: ...

Suppressed expression of transgenes in vivo is the major obstacle in the gene therapy. For the long-term expression, we utilized a chromatin insulator from sea urchin arylsulfatase (Ars) gene locus ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

Lentiviral vectors are increasingly popular as gene delivery tools for cell and gene therapies. Their value has been demonstrated within CAR-T and TCR therapies for blood malignancies that don’t ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...

The expansion of LENTIVERSE™ platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.

Lentiviral vectors are versatile gene delivery tools, capable of transducing a wide range of cell types. However, producing large volumes of high-quality lentiviruses can present several challenges.

Lentiviral Vector Market report encompasses a range of inhibitors as well as driving forces of the market which are analysed in both qualitative and quantitative manner so that readers and users get ...